{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:43:37Z","timestamp":1748587417572,"version":"3.30.2"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.gore.2024.101528","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T02:43:23Z","timestamp":1728614603000},"page":"101528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor"],"prefix":"10.1016","volume":"56","author":[{"given":"Jess","family":"Durbin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-6678","authenticated-orcid":false,"given":"Taylor A.","family":"Rives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dava","family":"Piecoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2024.101528_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2019.104562","article-title":"Cutaneous squamous cell carcinoma in the organ transplant recipient","volume":"103","author":"Bibee","year":"2020","journal-title":"Oral Oncol."},{"key":"10.1016\/j.gore.2024.101528_b0010","unstructured":"ClinicalTrials.gov [Internet]. 2023 [cited Jan 23, 2024]. Available from: https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.gore.2024.101528_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-8258(21)00757-5","article-title":"AdoRN Trial: Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly-diagnosed advanced-stage epithelial ovarian cancer","volume":"162","author":"Gaillard","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2024.101528_b0020","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.21037\/gs-20-325","article-title":"Secondary and tertiary ovarian cancer recurrence: what is the best management?","volume":"9","author":"Garzon","year":"2020","journal-title":"Gland Surg."},{"issue":"15_suppl","key":"10.1016\/j.gore.2024.101528_b0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6005","article-title":"Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer","volume":"38","author":"Matulonis","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.gore.2024.101528_b0030","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3498","article-title":"Update of the Management of Cutaneous Squamous-cell Carcinoma","volume":"100","author":"Maubec","year":"2020","journal-title":"Acta Derm Venereol."},{"issue":"17","key":"10.1016\/j.gore.2024.101528_b0035","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2024.101528_b0040","unstructured":"NCI. Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer2018 Jan 23, 2024. Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/cemiplimab-fda-squamous-cell-carcinoma."},{"key":"10.1016\/j.gore.2024.101528_b0045","unstructured":"Panel N. NCCN Guidelines: Squamous Cell Skin Cancer. 2023 Nov 9, 2023."},{"key":"10.1016\/j.gore.2024.101528_b0050","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. 2023. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"issue":"1","key":"10.1016\/j.gore.2024.101528_b0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-022-00655-8","article-title":"Immunotherapy in ovarian cancer","volume":"70","author":"Siminiak","year":"2022","journal-title":"Arch. Immunol. Ther. Exp. (warsz)."},{"key":"10.1016\/j.gore.2024.101528_b0060","article-title":"Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer - PubMed","volume":"194","author":"Wanying Bao","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"16","key":"10.1016\/j.gore.2024.101528_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164041","article-title":"PD-1 inhibitors in elderly and immunocompromised patients with advanced or metastatic cutaneous squamous cell carcinoma","volume":"15","author":"Yakobson","year":"2023","journal-title":"Cancers (basel)."},{"issue":"6","key":"10.1016\/j.gore.2024.101528_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061764","article-title":"Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients-A Comparison between Different Immunomodulating Conditions","volume":"15","author":"Zavdy","year":"2023","journal-title":"Cancers (basel)."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924002078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924002078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:01:37Z","timestamp":1734048097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578924002078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":14,"alternative-id":["S2352578924002078"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2024.101528","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2024.101528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101528"}}